ATS 2023 Respiratory Innovation Summit

During the ATS 2023 Respiratory Innovation Summit, APIE Therapeutics presented a poster demonstrating preclinical efficacy of APT101 in a lung fibrosis model

APIE Therapeutics Welcomes Jim Greenwood to its Board of Directors

Cary, NC — APIE Therapeutics, a preclinical pharmaceutical company pioneering novel and proprietary drugs to activate the apelin receptor (APJ), announced the appointment of Jim Greenwood, former president & CEO of the Biotechnology Innovation Organization (BIO), to its board of directors. “Jim is known in the industry for his long tenure as president and CEO […]

IPF Summit 2022

During the IPF Summit, APIE Therapeutics presented a poster describing the novel apelin receptor agonist (APT101) and its effects in models of acute and chronic lung injury